about
Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator.Parental evaluation of a telemonitoring service for children with Type 1 Diabetes.Towards a Run-to-Run Adaptive Artificial Pancreas: In Silico Results.Evaluating the Experience of Children With Type 1 Diabetes and Their Parents Taking Part in an Artificial Pancreas Clinical Trial Over Multiple Days in a Diabetes Camp Setting.Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe.Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home.Incorporation of inhaled insulin into the FDA accepted University of Virginia/Padova Type 1 Diabetes Simulator.2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.Multinight "bedside" closed-loop control for patients with type 1 diabetes.Circadian variability of insulin sensitivity: physiological input for in silico artificial pancreas.The university of Virginia/Padova type 1 diabetes simulator matches the glucose traces of a clinical trial.Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas.Hepatic insulin sensitivity in healthy and prediabetic subjects: from a dual- to a single-tracer oral minimal model.Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes.Personalized blood glucose prediction: A hybrid approach using grammatical evolution and physiological models.The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day.Accuracy of a CGM Sensor in Pediatric Subjects With Type 1 Diabetes. Comparison of Three Insertion Sites: Arm, Abdomen, and Gluteus.Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes.First use of model predictive control in outpatient wearable artificial pancreas.Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes
P50
Q27307805-F332A5DD-54EB-436F-B91B-7A7BE6C2882FQ30252858-67B53B6E-356B-468C-A7F2-381CAF16F194Q30274989-9CE806A8-BFA7-4176-A498-4A7DA28A1DD1Q30275404-01503ED7-D8FB-49A6-870D-2646212CD578Q30276765-16AC083C-20AC-4E57-8106-6FEB90B62855Q30276766-5B80C61E-7702-48F4-BD67-E0CB62E2625FQ30277800-F150209D-42E6-4E95-A453-A8BF06375E4CQ30278580-10478112-49DA-4CDC-9C9C-9C05493515DFQ30300933-9FB9CAF9-54CE-40EB-B149-550563357642Q30300948-9070A88B-5666-4CEC-9BB7-70D8485C0DF6Q30301086-40C5E400-12A1-4CE9-B274-59E3929FC3F9Q30384405-B8AC1C00-B088-4D7F-8E07-E7F7AA41CA8AQ30412117-13A20BB1-3EEB-4FAD-B2FD-3B902C3D6771Q35859162-BD47ABBF-604E-431A-AFD1-8D5F1BFDA182Q45062397-96B2C729-F795-4324-A64A-2EF61408B1AEQ47106534-941AAF0C-82D0-46A9-A27C-B048FE2CDCFFQ49943525-B692CEBD-EF09-4C3A-BDD2-2310DC9FBE6EQ50882390-99B9AF60-9A14-4C0E-88AF-40266C6D45B2Q50951947-229C43E1-E0F9-43BC-84DF-6522100DC935Q51092446-09CF7F6B-072C-4719-A401-B814C29CB901Q91747820-09B2C83B-F959-4D26-A47D-29AE849E3300
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberto Visentin
@ast
Roberto Visentin
@en
Roberto Visentin
@es
Roberto Visentin
@nl
Roberto Visentin
@sl
type
label
Roberto Visentin
@ast
Roberto Visentin
@en
Roberto Visentin
@es
Roberto Visentin
@nl
Roberto Visentin
@sl
prefLabel
Roberto Visentin
@ast
Roberto Visentin
@en
Roberto Visentin
@es
Roberto Visentin
@nl
Roberto Visentin
@sl
P106
P1153
55892448200
P21
P31
P496
0000-0002-5848-5990